Patient-reported outcomes with nivolumab plus cabozantinib in advanced kidney cancer

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib have been published in The Lancet Oncology this week. Previous trial results have shown that the nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice as many previously untreated renal cell carcinoma (RCC) patients responded […]

read more

Atezolizumab plus bevacizumab does not improve survival in kidney cancer

Results from the IMmotion151 phase III clinical trial were published in JAMA Oncology this week and showed that a combination of atezolizumab and bevacizumab did not improve overall survival time compared with sunitinib in patients with previously untreated, metastatic renal cell carcinoma (RCC). The researchers said they “do not have a clear explanation” for these […]

read more

Adjuvant pembrolizumab gets positive opinion from the European CHMP

We have just learnt that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), is recommending approval of pembrolizumab for the adjuvant treatment of people with intermediate to high risk renal cell carcinoma (RCC) following nephrectomy. The CHMP positive opinion will now be reviewed by the […]

read more

European Commission approves pembrolizumab plus lenvatinib as first-line treatment for advanced kidney cancer

The European Commission has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC) for use within the European Union (including Northern Ireland). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which […]

read more

First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy

A recent post hoc analysis of the CheckMate 214 trial looked at the nivolumab plus ipilimumab combination in 108 patients with advanced renal cell carcinoma (RCC) who had not had surgery to remove their cancer (nephrectomy). Patients were randomised to nivolumab plus ipilimumab every 3 weeks followed by nivolumab alone (53 patients) or sunitinib every […]

read more

Cabozantinib after progression of kidney cancer improves survival

In a recent study, the use of cabozantinib after progression of renal cell carcinoma (RCC) was assessed. Forty-five (45) patients continued with treatment with cabozantinib after their disease had progressed, and 44 patients switched to cabozantinib. Nearly 60% of patients had been treated with two or more prior treatments. Of these patients, most (85%) had […]

read more

FDA approves adjuvant pembrolizumab for intermediate-high risk kidney cancer

The Food and Drug administration (FDA) in the USA has approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate or high risk of recurrence following nephrectomy, or for RCC patients after having a nephrectomy and removal of metastases. Adjuvant therapy is medication that is given in addition to surgery to […]

read more

Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer

A recent study looked at the efficacy and safety of first-line treatment with a combination of immunotherapies (immune checkpoint inhibitors) for sarcomatoid renal cell carcinoma (RCC). The analysis included five clinical trials involving 568 patients with sarcomatoid RCC. All combinations that were looked at significantly improved progression-free survival and response rate. Combination treatments with nivolumab […]

read more

Updates to the European Association of Urology (EAU) Guidelines for Renal Cell Carcinoma

The European Association of Urology (EAU) Guidelines for Renal Cell Carcinoma (RCC) were updated in March 2021. The full updated guidelines can be found on our website by clicking here: Below is a summary of the most important changes: Use MRI and ultrasound for further characterisation of small renal masses, tumour thrombus and differentiation of […]

read more

Risks and benefits of adjuvant therapy for kidney cancer

Treatment of people with intermediate to high risk renal cell carcinoma (RCC) with medicine to prevent the cancer from coming back (adjuvant therapy) can benefit some patients, but it’s important for each patient to weigh the treatment benefit and potential risk of side effects on quality of life. Adjuvant therapy has been shown to delay […]

read more
Showing 1 to 10 of 539 results
  TOP